IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of: GOODWIN et al.

Serial No.: 09/079,785

Filed: May 15, 1998

Docket No.: 2804-用ECH CENTER 1600/29

Group Art Unit: 1646

Examiner: L. Spector

For: CD30 LIGAND OLIGOMERS AND POLYPEPTIDES (as amended)

TERMINAL DISCLAIMER UNDER 37 CFR 1.321(c)

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

Immunex Corporation, a corporation of the State of Washington and having a principal place of business at 51 University Street, Seattle, Washington 98101, represents that it is the assignee of application serial no. 09/079,785, filed May 15, 1998, for "CD30 LIGAND OLIGOMERS AND POLYPEPTIDES". The application was assigned to Immunex Corporation by virtue of the assignment recorded with the United States Patent and Trademark Office on July 18, 1994, at Reel/Frame 7066/0094, in grandparent application serial no. 08/225,989. Present application serial no. 09/079,785 is a divisional of U.S. application serial no. 08/580,014, which is a divisional of U.S. application serial no. 08/225,989.

Immunex Corporation hereby disclaims the terminal part of any patent granted on application serial no. 09/079,785, that would extend beyond the expiration date of U.S. Patent no. 5,480,981 (which patent issued from U.S. application serial no. 08/225,989). Immunex Corporation also agrees that any patent granted on application serial no. 09/079,785 shall be enforceable only for and during such period that the legal title to said patent (granted on the present application) is the same as the legal title to U.S. Patent no. 5,480,981. U.S. application serial no. 08/225,989 was assigned to Immunex Corporation by virtue of the assignment recorded with the United States Patent and Trademark Office on July 18, 1994, at Reel/Frame 7066/0094.

In accordance with 37 CFR 3.73(b), Immunex Corporation hereby certifies that the evidentiary documents regarding the chain of title of patent application serial no. 09/079,785 have been reviewed. Immunex Corporation hereby certifies that, to the best of its knowledge and belief, title is in the assignee seeking to take the action herein.

Disclaimer N 09/079,785

The Commissioner is hereby authorized to charge the \$110.00 fee required pursuant to 37 CFR 1.20(d) for this terminal disclaimer, to our Deposit Account no. 09-0089. A copy of this paper is submitted herewith for that purpose. The Commissioner is further authorized to charge any other fee required in connection with the enclosed papers, or to credit any overpayment, to Deposit Account 09-0089.

Immunex Corporation
51 University Street
Seattle, Washington 98101
(206) 389-4341 (direct line)

Respectfully submitted,

Kathryn A. Anderson Registration No. 32,172

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: January 13, 2000 Signed: Camila C. Surares